Amycretin
Amycretin — evidence, the "CagriSema in one molecule" story & status

Class: peptide
Synonyms: amycretin
Function tags: metabolic
obesity / weight
type-2 diabetes (investigational)
Overall evidence grade: B
WADA prohibited: no
Last updated: 2026-07-11

In brief: Amycretin is Novo Nordisk's first-in-class unimolecular GLP-1 + amylin agonist — the CagriSema concept in a single molecule, developed as both a pill and a weekly injection. Early-phase data are striking (~24% weight loss subcutaneously at 36 weeks; ~13% with the oral form at just 12 weeks, beating semaglutide at that timepoint), and Novo is taking both forms straight to Phase 3 in 2026. But it is early-stage (Phase 1b/2a) and not approved anywhere — the impressive numbers still need Phase 3 confirmation.

## Identity a single engineered peptide that activates **both** the **GLP-1 receptor** and the **amylin receptor** — the two pathways that CagriSema (#5) combines using *two* molecules, here united in **one**. Developed in **both a once-daily oral tablet and a once-weekly subcutaneous injection.** ## Mechanism (as proposed) a single molecule agonising **both the GLP-1 receptor** (hypothalamic appetite control, glucose-dependent insulin, glucagon suppression, slowed gastric emptying) **and the amylin receptor** (brainstem/area-postrema satiety, gastric emptying, glucagon) — the same complementary two-pathway logic as CagriSema, delivered in one agent. An orally bioavailable version of this is the headline pharmacology.

Evidence grades by outcome:
outcome: Weight loss — subcutaneous
grade: B
base: Phase 1b/2a (Lancet 2025, → −24.3% at 36 wk)
effect: Very large
caveat: Early-phase (Phase 1b/2a), small; needs Phase 3 confirmation; high trial withdrawal
outcome: Weight loss — oral
grade: B
base: Phase 1 (Lancet 2025, ~13.1% at 12 wk, > semaglutide's ~6%)
effect: Strong for an oral agent
caveat: Early, short (12 wk); Phase 3 pending
outcome: Type-2 diabetes (HbA1c)
grade: B
base: Phase 2 (n=448, up to −1.8%)
effect: Meaningful
caveat: Phase 2; not approved
outcome: Safety
base: Phase 1/2 (GI-predominant, mostly mild-moderate)
effect: Class-consistent
caveat: GI events frequent (as with GLP-1/amylin); long-term profile unestablished; investigational

Legal status:
region: INT
status: See note
note: - Everywhere — investigational, not approved. Not available by prescription or compounding outside clinical trials.
- Gray market: "research" amycretin sold online is unapproved and unregulated — unknown purity/dose (and, being early-stage, authenticity is especially doubtful).
- This venture: not a sellable lane — an investigational drug.

Cosmetic claims:

Note: Reference entry — NOT a sellable lane, NOT approved. The hottest emerging obesity molecule: it folds the CagriSema idea (GLP-1 + amylin) into one molecule, in both oral and injectable forms. Investigational; racing into Phase 3. No dosing published here.
Status note: fast-moving — re-check Phase 3 progress

Sources:
Gasiorek A, et al. Safety, tolerability, PK/PD of the first-in-class GLP-1 and amylin receptor agonist amycretin: a first-in-human Phase 1 study (oral). Lancet. 2025.
Dahl K, et al. Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: a Phase 1b/2a study. Lancet. 2025.
Novo Nordisk — Phase 2 T2D topline (2025–2026); Phase 3 advancement announcement (both oral + subcutaneous, Q1 2026).